Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fate Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

While some stem cell companies strive to develop neatly packaged products for specific medical niches, and some aim to supply research tools others will use, Fate Therapeutics is planning to do all that and more. The La Jolla, CA-based start-up founded in November 2007 has recruited an all-star team of scientists, clinicians, executives, and investors who together are pursuing the ultimate prize-the ability to restore health to diseased or damaged cells, and to find new therapeutics for many kinds of conditions that currently have limited or no treatment options.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091774

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel